Glycosylation of antibody molecules: Structural and functional significance

Chemical Immunology

Volumn 65, Issue , 1997, Pages 111-128

  Jefferis, Roy ^a   Lund, John ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLOBULAR PROTEIN; IMMUNOGLOBULIN G;

ANTIBODY STRUCTURE; ARTICLE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; CARBOHYDRATE SEQUENCE; GLYCOSYLATION; HUMANS; IMMUNOGLOBULINS; MOLECULAR SEQUENCE DATA;

EID: 0031015976     PISSN: 10150145     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Dwek R: Glycobiology - towards understanding the function of sugars. Biochem Soc Trans 1995; 23:1-25.
2. Jenkins N, Curling E: Glycosylation of recombinant proteins: Problems and prospects. Enzyme Microb Technol 1995;16:354-364.
3. Schaffner G, Haase M, Geiss S: Criteria for investigation of the product equivalence of monoclonal antibodies for therapeutic and in vivo diagnostic use in case of change in manufacturing process. Biologicals 1995;23:253-259.
4. Burton D, Woof JM: Antibody effector functions. Adv Immunol 1992;52:1-48.
5. Beale D, Feinstein A: Structure and function of the constant regions of immunoglobulins. Q Rev Biophys 1976;9:135-180.
6. Jefferis R, Lund J, Mizitani H, Nakagawa H, Kawazoe Y, Arata Y, Takahashi N: A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins. Biochem J 1990; 268:529-537.
7. Jefferis R: Glycosylation of antibody molecules: functional significance. Glycoconjug J 1993;10: 357-361.
8. Jefferis R, Lund J, Goodall M: Recognition sites on human IgG for Fcγ receptors: The role of glycosylation. Immunol Lett 1995;44:111-117.
9. Endo T, Wright A, Morrison SL, Kobata A: Glycosylation of the variable region of immunoglobulin G-sitc-spccific maturation of the sugar chains. Mol Immunol 1995;32:934-940.
10. Leibiger H, Hansen A, Schoenherr G, Seifert M, Wustner D, Stigler R, Marx U: Glycosylation analysis of a polyreactive human monoclonal IgG antibody derived from a human-mouse heterohybridoma. Mol Immunol 1995;32:595-602.
11. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB: Agalactosyl IgG activates complement via mannose-binding protein. Nat Med 1995;1:237-243.
12. Padlan E: x-Ray diffraction studies of antibody constant regions, in Metzger H (ed): Fc Receptors and the Action of Antibodies. Washington. American Society for Microbiology, 1990, pp 12-30.
13. Lund J, Tanaka T, Takahashi N, Sarmay G, Arata Y, Jefferis R: A protein structural change in aglycosylated IgG3 correlates with loss of huFcRI and huFcRIII binding and/or activation. Mol Immunol 1990;27:1145-1153.
14. Matsuda H, Nakamura S, Ichikawa Y, Kozai K, Takano R, Nose M, Endo S, Nishimura Y, Arata Y: Proton nuclear magnetic resonance studies of the structure of the Fc fragment of human immunoglobulin G1: Comparisons of native and recombinant proteins. Mol Immunol 1990;27:571-579.
15. Hindley S, Gao Y, Nash P, Sautes C, Lund J, Goodall M, Jefferis R: The interaction of IgG with FcγRII: Involvement of the lower hinge binding site as probed with NMR. Biochem Soc Trans 1993;21:3375.
16. Lund J, Winter G, Jones PT, Pound JD, Tanaka T, Walker MR, Artymiuk PJ, Arata Y, Burton DR, Jefferis R, Woof JM: Human FcγRI and FcγRII interact with distinct but overlapping binding sites on the human IgG. J Immunol 1991;147:2657-2662.
17. Sarmay G, Lund J, Rozsnyay Z, Gergely J, Jefferis R: Mapping and comparison of the interaction sites on the Fc region of IgG responsible for triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fc receptor. Mol Immunol 1992;29:633-639.
18. H2 domain and is modulated by the hinge region. J Exp Med 1991;173:1483-1491.
19. Warmerdam PAM, van de Winkle JGJ, Gosseli EJ, Capel PJA: A single amino acid in the second domain of the human Fcγ receptor II is critical for human IgG2 binding. J Immunol 1991;172: 19-25.
20. Pound JD, Lund J, Jefferis R: Aglycosylated chimeric human IgG3 can trigger the human phagocyte respiratory burst. Mol Immunol 1993;30:233-241.
21. Walker MR, Lund J, Thompson KM, Jefferis R: Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing FcγRI and FcγRII receptors. Biochem J 1989;259:347-353.
22. Routledge EG, Falconer ME, Pope H, Lloyd IS, Waldmann H: The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody. Transplantation 1995;60: 847-853.
23. Kumpel BM, Rademacher TW Rook GAW, Williams PJ, Wilson IBH: Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity. Hum Antibody Hybridomas 1994;5:143-151.
24. Lund J, Takahashi N, Pound JD, Goodall M, Nakagawa H, Jefferis R: Oligosaccharide-protein interactions in IgG can modulate recognition by Fcγ receptors. FASEB J 1995;9:115-119.
25. Tsuchiya N, Endo T, Matsuta K, Yoshinoya S, Aikawa T, Kosuge E, Takeuchi F, Miyamoto T, Kobata A: Effects of galactose depletion from oligosaccharide chains on immunological activities of human IgG. J Rheumatol 1989;16:285-290.
26. Lifely M, Hale C, Boyce S, Keen MJ, Phillips J: Glycosylation and biological activities of Campath-1H expressed in different cell lines and grown under different culture conditions. Glycobiology 1995; 5:813-822.
27. Lund J, Takahashi N, Nakagawa H, Goodall M, Bentley T, Hindley SA, Tyler R, Jefferis R: Control of IgG/Fc glycosylation: A comparison of oligosaccharides from chimeric human/mouse and mouse subclass immunoglobulin Gs. Mol Immunol 1993;30:741-748.
28. Boyd PN, Lines AC, Patel AK: The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol 1995;32:1311-1318.
29. H2 associated carbohydrate structure on the functional properties and in vivo fate of human immunoglobulin 1. J Exp Med 1994;180:1087-1096.
30. Horwitz AH, Chang CP, Better M, Hellstrom KE: Secretion of functional antibody and Fab fragment from yeast cells. Proc Natl Acad Sci USA 1988;85:8678-8682.
31. H2 domains. Mol Immunol 1992;219:213-220.
32. Kim JK, Tsen MF, Ghetie V, Ward ES: Evidence that the hinge region plays a role in maintaining serum levels of the munne IgG1 molecule. Mol Immunol 1995;32:467-475.
33. Goodrick J, Kumpel B, Pamphilon D, Fraser I, Chapman G, Dawes B, Anstee D: Plasma half-lives and bioavailability of human monoclonal Rh D antibodies BRAD-3 and BRAD-5 following intramuscular injection into RhD-negative volunteers. Clin Exp Immunol 1994;98:17-20.
34. Duncan AR, Winter G: The binding site for C1q on IgG. Nature 1988;332:738-740.
35. H2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, FcγRI and FcγRII binding. Immunology 1995;86:319-324.
36. Tao MH, Smith RIF, Morrison SL: Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med 1993;178:661-667.
37. Dorai H, Mueller BM, Reisfeld RA, Gillies SD: Aglycosylated chimeric mouse/human IgG1 antibody retains some effector function. Hybridoma 1991;10:211-217.
38. Parekh RB, Dwek RA, Sutton JB, Fernandes DL, Leung A, Stanworth D, Mizuochi T, Taniguchi T, Matsuta K, Takeuchi F, Nagano Y, Miyamoto T, Kobata A: Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985;316:452-457.
39. Jefferis R, Nik Jaafar MIB, Steinitz M: Immunogenic and antigenic epitopes of immunoglobulins. VIII. A human monoclonal rheumatoid factor having specificity for a discontinuous epitope determined by histidine/arginine interchange as residue 435 of immunoglobulin G. Immunol Lett 1984; 7:191-194.
40. Soltys AS, Hay FC, Bond A, Axford AS, Jones MG, Randen I, Thompson KM, Natvig JB: The binding of synovial tissue derived monoclonal human immunoglobulin M rheumatoid factors to immunoglobulin G preparations of differing galactose content. Scand J Immunol 1994;40:135-143.
41. Artandi SE, Canfield SM, Tao MH, Calame KL, Morrison SL, Bonagura VR: Molecular analysis of IgM rheumatoid factor binding to chimeric IgG. J Immunol 1991;146:603-610.
42. Bonagura VR, Artandi SE, Davidson A, Randen I, Agostino N, Thompson K, Natvig J, Morrison SL: Mapping studies reveal unique epitopes on IgG recognised by rheumatoid arthritis-derived monoclonal rheumatoid factors. J Immunol 1993;151:3840-3852.
43. Rajnavolgyi E, Fazekas GY, Lund J, Daeron M, Teillaud J, Jefferis R, Fridman W, Gergely J: Activation of effector functions by immune complexes of mouse IgG2a with isotype specific autoantibodies. Immunology 1995;85:645-654.
44. Muraoka S, Shulman MJ: Structural requirements for IgM assembly and cytolytic activity. Effects of mutations in the oligosaccharide acceptor site at Asn-402. J Immunol 1989;142:695-701.
45. Shulman MJ, Pennel N, Collins C, Hozumi N: Activation of complement by immunoglobulin M is impaired by the substitution serine-406→asparagine in the immunoglobulin μ heavy chain. Proc Natl Acad Sci USA 1986;863:7678-7682.
46. Stanley P, Ioffe E: Glycosyltransferase mutants - key to new insights in glycobiology. FASEB J 1995;9:1436-1444.
47. Galili U, Shohet SB, Kobrin E, Stults CLM, Macher BA: Man, apes and old world monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells. J Biol Chem 1988;263:17755-17762.
48. Borraebeck CAK, Malmbor AC, Ohlin M: Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics? Immunol Today 1993;14:477-479.
49. Ashford DA, Alaf CD, Gamble VM: Site-specific glycosylation of rat and human soluble CD4 variants expressed in CHO cells. J Biol Chem 1993;268:3260-3267.
50. Tandai M, Endo T, Sasaki S, Masuho Y, Kochibe N, Kobata A: Structural study of the sugar moieties of monoclonal antibodies secreted by human-mouse hybridoma. Arch Biochem Biophys 1991;291:339-348.
51. Yu Ip C, Miller WJ, Silberklang M, Mark GE, Ellis RW, Huang L, Glusha J, Van Halbeek H, Zhu J, Alhadeff JA: Structural characterisation of the N-glycans of a humanized anti-CD 18 murine immunoglobulin. G Arch Biochem Biophys 1994;308:387-399.
52. Montano RM, Romano EL: Human monoclonal anti-Rh antibodies produced by human-mouse heterohybridomas express the gal α(1-3) Gal epitope. Hum Antibody Hybridomas 1995;5:152-156.
53. Davidson DJ, Castellino FJ: Structures of the Asn-289 linked oligosaccharide assembled on human plasminogen expressed in Mamestra brassicae cell line (IZD.MB503). Biochemistry 1991;30:6689-6696.
54. Jarvis DL, Finn EE: Biochemical analysis of the N-glycosylation pathway in baculovirus-infected insect cells. Virology 1995;212:500-511.
55. van Dijk W, Turner GA, Mackiewicz A: Changes in glycosylation of acute-phase proteins in health and disease: Occurrence, regulation and function. Glycosyl Dis 1994;1:5-14.
56. Farooq M, Takahashi N, Arrol H, Drayson M, Jefferis R: Glycosylation of IgG antibody molecules in multiple myeloma. 1st Electronic Glycoscience Conference - proceedings, in press.
57. Nakao H, Nishikawa A, Nishiura T, Kanayama Y, Tarui S, Taniguchi N: Hypogalactosylation of immunoglobulin G sugar chains and elevated serum I1-6 in Castleman's disease. Clin Chim Acta 1991;197:221-228.
58. Anderson DR, Atkinson PH, Grimes WJ: Major carbohydrate structures at five glycosylation sites on murine IgM determined by high resolution IH-NMR spectroscopy. Arch Biochem Biophys 1985;13:605-618.
59. Mellis SJ, Baenziger JU: Structures of the oligosaccharides present at the 3 asparagine-linked glycosylation sites of human IgD. J Biol Chem 1983;258:11546-11555.
60. Mellis SJ, Baenziger JU: Structures of the O-glycosidically linked oligosaccharides of human IgD. J Biol Chem 1983;258:11557-11563.
61. Tachibana H, Taniguchi K, Ushio Y, Teruya K, Osada K, Murakami H: Changes of monosaccharide availability of human hybridomas lead to alteration of biological properties of human monoclonal antibody. Cytotechnology 1994;16:151-157.
62. Leung SO, Losman LMJ, Govindan SV, Griffiths GL, Goldenberg DM, Hansen HJ: Engineering a unique glycosylation site for site-specific conjugation of haptens to antibody fragments. J Immunol 1995;154:5919-5926.
63. Lund J, Takahashi N, Pound JD, Goodall M, Jefferis R: Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human FcγRI, and influence the synthesis of its oligosaccharide chains. J Immunol 1996, in press.